1 |
王佳丽, 韩明哲. 异基因造血干细胞移植后植入功能不良发生机制研究进展[J].中华血液学杂志, 2019, 40(9):792-795.
|
2 |
黄爱杰, 胡晓霞, 王健民. 异基因造血干细胞移植术后血小板减少研究进展[J]. 中国实验血液学杂志, 2017, 25(1):270-275.
|
3 |
Zhu L, Liu J, Kong P, et al. Analysis of the efficacy and safety of avatrombopag combined with MSCs for the treatment of thrombocytopenia after allogeneic hematopoietic stem cell transplantation[J]. Front Immunol, 2022, 13:910893.
|
4 |
Huang A, Zhao X, Li M, et al. Suppression of hematopoietic primitive cells in patients with secondary failure of platelet recovery after acute graft-versus-host disease[J]. Biol Blood Marrow Transplant, 2020, 26(10):1840-1854.
|
5 |
王恒, 邱婷婷, 徐开林. 异基因造血干细胞移植后继发性血小板减少患者的危险因素及预后意义分析[J]. 徐州医科大学学报, 2022, 42(3):170-174.
|
6 |
申彪, 庞爱明, 姜尔烈. 异基因造血干细胞移植后血小板减少发病机制的研究进展[J]. 中国细胞生物学学报, 2022, 44(1):159-164.
|
7 |
薛松, 刘夫红, 张永平, 等. 脐血间充质干细胞联合艾曲波帕治疗异基因造血干细胞移植后移植物功能不良的临床研究[J]. 国际输血及血液学杂志, 2022, 45(2):132-139.
|
8 |
Man Y, Lu Z, Yao X, et al. Recent advancements in poor graft function following hematopoietic stem cell transplantation[J]. Front Immunol, 2022, 13:911174.
|
9 |
Luo Y, Shao L, Chang J, et al. M1 and M2 macrophages differentially regulate hematopoietic stem cell self-renewal and ex vivo expansion[J]. Blood Adv, 2018, 2(8):859-870.
|
10 |
Zhao HY, Lyu ZS, Duan CW, et al. An unbalanced monocyte macrophage polarization in the bone marrow microenvironment of patients with poor graft function after allogeneic haematopoietic stem cell transplantation[J]. Br J Haematol, 2018, 182(5):679-692.
|
11 |
Zhao HY, Zhang YY, Xing T, et al. M2 macrophages, but not M1 macrophages, support megakaryopoiesis by upregulating PI3K-AKT pathway activity[J]. Signal Transduct Target Ther, 2021, 6(1): 234.
|
12 |
Li T, Luo C, Zhang J, et al. Efficacy and safety of mesenchymal stem cells co-infusion in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis[J]. Stem Cell Res Ther, 2021, 12(1):246.
|
13 |
Crippa S, Santi L, Berti M, et al. Role of ex vivo expanded mesenchymal stromal cells in determining hematopoietic stem cell transplantation outcome[J]. Front Cell Dev Biol, 2021, 9:663316.
|
14 |
Fathi E, Sanaat Z, Farahzadi R. Mesenchymal stem cells in acute myeloid leukemia: a focus on mechanisms involved and therapeutic concepts[J]. Blood Res, 2019, 54(3):165-174.
|
15 |
Fathi E, Valipour B, Sanaat Z, et al. Interleukin-6, -8, and TGF-β secreted from mesenchymal stem cells show functional role in reduction of telomerase activity of leukemia cell via Wnt5a/β-catenin and P53 pathways[J]. Adv Pharm Bull, 2020, 10(2):307-314.
|
16 |
Diehl R, Ferrara F, Müller C, et al. Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches[J]. Cell Mol Immunol, 2017,14(2):146-179.
|
17 |
Pinho S, Frenette PS. Haematopoietic stem cell activity and interactions with the niche[J]. Nat Rev Mol Cell Biol, 2019, 20(5):303-320.
|
18 |
Prabahran A, Koldej R, Chee L, et al. Clinical features, pathophysiology, and therapy of poor graft function post-allogeneic stem cell transplantation[J]. Blood Adv, 2022, 6(6):1947-1959.
|
19 |
Song Y, Zhao HY, Lyu ZS, et al. Dysfunctional bone marrow mesenchymal stem cells in patients with poor graft function after allogeneic hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2018, 24(10):1981-1989.
|
20 |
Zhao Y, Gao F, Shi J, et al. Incidence, risk factors, and outcomes of primary poor graft function after allogeneic hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2019, 25(9):1898-1907.
|
21 |
Kong Y, Song Y, Tang FF, et al. N-acetyl-L-cysteine improves mesenchymal stem cell function in prolonged isolated thrombocytopenia post-allotransplant[J]. Br J Haematol, 2018, 180(6): 863-878.
|
22 |
Gilreath J, Lo M, Bubalo J. Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists[J]. Drugs, 2021, 81(11):1285-1305.
|
23 |
Mahat U, Rotz SJ, Hanna R. Use of thrombopoietin receptor agonists in prolonged thrombocytopenia after hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2020, 26(3): e65-e73. doi: 10.1016/j.bbmt.2019.12.003.Epub 2019 Dec 9.
|
24 |
Michelson AD, Smolensky Koganov E, Forde EE, et al. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease[J]. J Thromb Haemost, 2018, 16(12):2515-2519.
|
25 |
Alvarado LJ, Huntsman HD, Cheng H, et al. Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ[J]. Blood, 2019, 133(19):2043-2055.
|
26 |
Mei H, Chen X, Zhou J, et al. Safety and efficacy of hetrombopag in patients with chronic immune thrombocytopenia: a single-arm, open-label, multi-center phase 1 study[J]. Ann Transl Med, 2022, 10(2):30.
|
27 |
Servais S, Baron F, Lechanteur C, et al. Multipotent mesenchymal stromal cells as treatment for poor graft function after allogeneic hematopoietic cell transplantation: A multicenter prospective analysis[J]. Front Immunol, 2023, 14:1106464.
|
28 |
Güven ZT, Çelik S, Eser B, et al. Eltrombopag for treatment of thrombocytopenia following hematopoietic stem cell transplantation[J]. Turk J Haematol, 2022, 39(2):103-108.
|
29 |
王怡然, 张素平, 李丽, 等. 艾曲泊帕治疗异基因造血干细胞移植后持续性血小板减少的多中心临床研究[J].郑州大学学报(医学版), 2021, 56(2): 253-258.
|
30 |
马艳茹, 黄晓军, 莫晓冬, 等. 艾曲波帕治疗异基因造血干细胞移植后难治性血小板减少的临床研究[J].中华血液学杂志, 2016, 37(12):1065-1069.
|
31 |
Yan F, Lu N, Gu Z, et al. Eltrombopag in the treatment of patients with persistent thrombocytopenia after haploidentical peripheral blood stem cell transplantation:a single-center experience[J]. Ann Hematol, 2022,101(2):397-408.
|
32 |
刘恩伊,方鹏,信红亚,等. 阿伐曲泊帕治疗异基因造血干细胞移植后血小板减少症疗效与安全性的14例真实世界数据评价[J]. 中南大学学报(医学版), 2023, 48(3):376-385.
|
33 |
Wang M, Feng R, Zhang JM, et al. Dysregulated megakaryocyte distribution associated with nestin+ mesenchymal stem cells in immune thrombocytopenia[J]. Blood Adv, 2019, 3(9): 1416-1428.
|